Role of homologous recombination/recombineering on human adenovirus genome engineering:Not the only but the most competent solution  

作　　者：Lisa-Marie Dawson Montaha Alshawabkeh Katrin Schröer Fatima Arakrak Anja Ehrhardt Wenli Zhang 

机构地区：[1]Virology and Microbiology,Center for Biomedical Education and Research(ZBAF),School of Medicine,Faculty of Health,Witten/Herdecke University,Stockumer Str.1058453 Witten,Germany

出　　处：《Engineering Microbiology》2024年第1期90-107,共18页工程微生物学（英文）

基　　金：the DFG grant EH 192/5-3(to AE),the internal grant program(project IFF 2024-91);f the Faculty of Health at Witten/Herdecke University(WZ and KS)and the PhD program at Witten/Herdecke University(LK).

摘　　要：Adenoviruses typically cause mild illnesses,but severe diseases may occur primarily in immunodeficient individuals,particularly children.Recently,adenoviruses have garnered significant interest as a versatile tool in gene therapy,tumor treatment,and vaccine vector development.Over the past two decades,the advent of recombineering,a method based on homologous recombination,has notably enhanced the utility of adenoviral vectors in therapeutic applications.This review summarizes recent advancements in the use of human adenoviral vectors in medicine and discusses the pivotal role of recombineering in the development of these vectors.Additionally,it highlights the current achievements and potential future impact of therapeutic adenoviral vectors.

关 键 词：Adenoviral vector Gene therapy Homologous recombination Oncolytic virus Vaccine vector 

分 类 号：Q93[生物学—微生物学]